Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characteristics of an ideal rotavirus vaccine.
Reisinger KS, Block SL. Reisinger KS, et al. Among authors: block sl. Clin Pediatr (Phila). 2008 Jul;47(6):555-63. doi: 10.1177/0009922808314903. Epub 2008 May 8. Clin Pediatr (Phila). 2008. PMID: 18467670
Long-term study of a quadrivalent human papillomavirus vaccine.
Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS, Mehlsen J, Chatterjee A, Iversen OE, Sings HL, Shou Q, Sausser TA, Saah A. Ferris D, et al. Among authors: block sl. Pediatrics. 2014 Sep;134(3):e657-65. doi: 10.1542/peds.2013-4144. Epub 2014 Aug 18. Pediatrics. 2014. PMID: 25136050 Clinical Trial.
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.
Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF Jr, Reisinger KS; Protocol 016 Study Group. Block SL, et al. Pediatrics. 2006 Nov;118(5):2135-45. doi: 10.1542/peds.2006-0461. Pediatrics. 2006. PMID: 17079588
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.
Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S, Alvarez FB, Barr E. Reisinger KS, et al. Among authors: block sl. Pediatr Infect Dis J. 2007 Mar;26(3):201-9. doi: 10.1097/01.inf.0000253970.29190.5a. Pediatr Infect Dis J. 2007. PMID: 17484215 Clinical Trial.
An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.
Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, Sings HL, Perez G, Haupt RM, Saah AJ, Lievano F, Velicer C, Drury R, Kuter BJ. Vichnin M, et al. Among authors: block sl. Pediatr Infect Dis J. 2015 Sep;34(9):983-91. doi: 10.1097/INF.0000000000000793. Pediatr Infect Dis J. 2015. PMID: 26107345 Review.
Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
Nolan T, Bernstein DI, Block SL, Hilty M, Keyserling HL, Marchant C, Marshall H, Richmond P, Yogev R, Cordova J, Cho I, Mendelman PM; LAIV Study Group. Nolan T, et al. Among authors: block sl. Pediatrics. 2008 Mar;121(3):508-16. doi: 10.1542/peds.2007-1064. Pediatrics. 2008. PMID: 18310199 Clinical Trial.
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.
Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, Wittes J, Iacuzio D, Piedra P, Treanor J, King J, Kotloff K, Bernstein DI, Hayden FG, Zangwill K, Yan L, Wolff M. Belshe RB, et al. Among authors: block sl. J Pediatr. 2000 Feb;136(2):168-75. doi: 10.1016/s0022-3476(00)70097-7. J Pediatr. 2000. PMID: 10657821 Clinical Trial.
177 results